80 related articles for article (PubMed ID: 11362424)
1. HIV-1 immunogen.
Lein B
PI Perspect; 1995 May; (no 16):17. PubMed ID: 11362424
[TBL] [Abstract][Full Text] [Related]
2. Remune trials recruiting.
PI Perspect; 1996 Sep; (No 19):17. PubMed ID: 11363901
[TBL] [Abstract][Full Text] [Related]
3. FDA advisory committees meet January 26 on Salk HIV-1 immunogen.
AIDS Treat News; 1995 Jan; (No 214):1-2. PubMed ID: 11362184
[TBL] [Abstract][Full Text] [Related]
4. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
5. Honing the immune attack on HIV.
Gilden D
GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus antibodies and the vaccine problem.
Chiodi F; Weiss RA
J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
9. HIV vaccine efficacy trials: towards the future of HIV prevention.
Kim D; Elizaga M; Duerr A
Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
[TBL] [Abstract][Full Text] [Related]
10. A review of vaccine research and development: the human immunodeficiency virus (HIV).
Girard MP; Osmanov SK; Kieny MP
Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against HIV.
Norley S; Kurth R
Immunobiology; 1992 Feb; 184(2-3):193-207. PubMed ID: 1587543
[TBL] [Abstract][Full Text] [Related]
12. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Mascolini M
AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022
[TBL] [Abstract][Full Text] [Related]
13. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
14. HIV-specific immune responses restored by HIV immunogen plus antiretroviral suppression.
James JS
AIDS Treat News; 1998 Jul; (No 298):1-5. PubMed ID: 11365597
[TBL] [Abstract][Full Text] [Related]
15. The immune response to HIV: implications for vaccine development.
Bolognesi DP
Semin Immunol; 1993 Jun; 5(3):203-14. PubMed ID: 8347841
[TBL] [Abstract][Full Text] [Related]
16. Update on HIV vaccines.
Meldorf M; Corey L
STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
[TBL] [Abstract][Full Text] [Related]
17. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
[TBL] [Abstract][Full Text] [Related]
18. New vaccine+HAART treatment trial enrolling at NIH. National Institutes of Health.
James JS
AIDS Treat News; 1998 Aug; (No 300):3-4. PubMed ID: 11365687
[TBL] [Abstract][Full Text] [Related]
19. AIDS vaccine: efficacy, safety and ethics.
Veljkovic V; Veljkovic N; Glisic S; Ho MW
Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccines for immunodeficiency viruses.
Robinson HL
AIDS; 1997; 11 Suppl A():S109-19. PubMed ID: 9451974
[No Abstract] [Full Text] [Related]
[Next] [New Search]
